Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) — TRIVERSYTI

COPD (Chronic Obstructive Pulmonary Disease) Clinical Trial

Official title:
A 24-week, Double Blind, Double Dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group,Active Controlled Clinical Trial of Fixed Combination of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide Administered Via pMDI (CHF 5993) Versus the Fixed Combination of Budesonide Plus Formoterol Fumarate (Symbicort® Turbuhaler®) in Patients With Chronic Obstructive Pulmonary Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort® Turbuhaler® in terms of pulmonary function, as well as to assess its safety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

COPD (Chronic Obstructive Pulmonary Disease)
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT03197818
Study type	Interventional
Source	Chiesi Farmaceutici S.p.A.
Contact
Status	Completed
Phase	Phase 3
Start date	December 14, 2016
Completion date	May 26, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05553847` - Automated Oxygen Titration in Daily Life in Patients With COPD on Home Oxygen	N/A
Completed	`NCT02859194` - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients	N/A
Not yet recruiting	`NCT03921983` - Non Invasive Evaluation of Muscle Hypoxia in COPD Patient (EVANIMUS)	N/A
Recruiting	`NCT05572632` - Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD	N/A
Recruiting	`NCT06075095` - A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD	Phase 3
Recruiting	`NCT06283966` - A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease	Phase 3
Not yet recruiting	`NCT06158633` - A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
Recruiting	`NCT05811832` - Evaluation in Elderly Individuals With Chronic Obstructive Pulmonary Disease(COPD)
Completed	`NCT02867761` - RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative	Phase 3